{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T09:07:00Z","timestamp":1769764020127,"version":"3.49.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,29]]},"DOI":"10.7759\/cureus.102570","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T17:48:02Z","timestamp":1769708882000},"source":"Crossref","is-referenced-by-count":0,"title":["Idiopathic Hypoparathyroidism in an Osteoporosis Patient Receiving Denosumab Therapy"],"prefix":"10.7759","author":[{"given":"Louie S","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darcy S","family":"Tokunaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sian Yik","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-3908","article-title":"Epidemiology and diagnosis of hypoparathyroidism","volume":"101","author":"Clarke BL","year":"2016","unstructured":"Clarke BL, Brown EM, Collins MT, et al.. Epidemiology and diagnosis of hypoparathyroidism. J Clin Endocrinol Metab. 2016, 101:2284-99. 10.1210\/jc.2015-3908","journal-title":"J Clin Endocrinol Metab"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-3909","article-title":"Presentation of hypoparathyroidism: etiologies and clinical features","volume":"101","author":"Shoback DM","year":"2016","unstructured":"Shoback DM, Bilezikian JP, Costa AG, et al.. Presentation of hypoparathyroidism: etiologies and clinical features. J Clin Endocrinol Metab. 2016, 101:2300-12. 10.1210\/jc.2015-3909","journal-title":"J Clin Endocrinol Metab"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa113","article-title":"Hypoparathyroidism","volume":"105","author":"Bilezikian JP","year":"2020","unstructured":"Bilezikian JP. Hypoparathyroidism. J Clin Endocrinol Metab. 2020, 105:1722-36. 10.1210\/clinem\/dgaa113","journal-title":"J Clin Endocrinol Metab"},{"key":"ref4","article-title":"Hypoparathyroidism and Pseudohypoparathyroidism","author":"Bastepe M","year":"2000","unstructured":"Bastepe M, Gensure RC. Hypoparathyroidism and Pseudohypoparathyroidism. Endotext, South Dartmouth (MA); 2000."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/cen.12188","article-title":"Parathyroid hormone changes following denosumab treatment in postmenopausal osteoporosis","volume":"79","author":"Makras P","year":"2013","unstructured":"Makras P, Polyzos SA, Papatheodorou A, et al.. Parathyroid hormone changes following denosumab treatment in postmenopausal osteoporosis. Clin Endocrinol (Oxf). 2013, 79:499-503. 10.1111\/cen.12188","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.12517","article-title":"Denosumab: prevention and management of hypocalcemia, osteonecrosis of the jaw and atypical fractures","volume":"13","author":"Pittman K","year":"2017","unstructured":"Pittman K, Antill YC, Goldrick A, et al.. Denosumab: prevention and management of hypocalcemia, osteonecrosis of the jaw and atypical fractures. Asia Pac J Clin Oncol. 2017, 13:266-76. 10.1111\/ajco.12517","journal-title":"Asia Pac J Clin Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.28239","article-title":"Severe hypocalcemia with denosumab among older female dialysis-dependent patients","volume":"331","author":"Bird ST","year":"2024","unstructured":"Bird ST, Smith ER, Gelperin K, et al.. Severe hypocalcemia with denosumab among older female dialysis-dependent patients. JAMA. 2024, 331:491-9. 10.1001\/jama.2023.28239","journal-title":"JAMA"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.4691","article-title":"Evaluation and management of hypoparathyroidism summary statement and guidelines from the second international workshop","volume":"37","author":"Khan AA","year":"2022","unstructured":"Khan AA, Bilezikian JP, Brandi ML, et al.. Evaluation and management of hypoparathyroidism summary statement and guidelines from the second international workshop. J Bone Miner Res. 2022, 37:2568-85. 10.1002\/jbmr.4691","journal-title":"J Bone Miner Res"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.4804","article-title":"Hypocalcemia risk of denosumab across the spectrum of kidney disease: a population-based cohort study","volume":"38","author":"Cowan A","year":"2023","unstructured":"Cowan A, Jeyakumar N, McArthur E, et al.. Hypocalcemia risk of denosumab across the spectrum of kidney disease: a population-based cohort study. J Bone Miner Res. 2023, 38:650-8. 10.1002\/jbmr.4804","journal-title":"J Bone Miner Res"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-015-3380-y","article-title":"Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports","volume":"27","author":"Aubry-Rozier B","year":"2016","unstructured":"Aubry-Rozier B, Gonzalez-Rodriguez E, Stoll D, Lamy O. Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports. Osteoporos Int. 2016, 27:1923-5. 10.1007\/s00198-015-3380-y","journal-title":"Osteoporos Int"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1093\/jbmr\/zjaf037","article-title":"Denosumab discontinuation in the clinic: implications of rebound bone turnover and emerging strategies to prevent bone loss and fractures","volume":"40","author":"Kumar S","year":"2025","unstructured":"Kumar S, Wang M, Kim AS, et al.. Denosumab discontinuation in the clinic: implications of rebound bone turnover and emerging strategies to prevent bone loss and fractures. J Bone Miner Res. 2025, 40:1017-34. 10.1093\/jbmr\/zjaf037","journal-title":"J Bone Miner Res"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3337","article-title":"Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension","volume":"33","author":"Cummings SR","year":"2018","unstructured":"Cummings SR, Ferrari S, Eastell R, et al.. Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension. J Bone Miner Res. 2018, 33:190-8. 10.1002\/jbmr.3337","journal-title":"J Bone Miner Res"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3110","article-title":"Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases","volume":"32","author":"Anastasilakis AD","year":"2017","unstructured":"Anastasilakis AD, Polyzos SA, Makras P, et al.. Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases. J Bone Miner Res. 2017, 32:1291-6. 10.1002\/jbmr.3110","journal-title":"J Bone Miner Res"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2018.11.012","article-title":"Skeletal manifestations of hypoparathyroidism","volume":"120","author":"Rubin MR","year":"2019","unstructured":"Rubin MR. Skeletal manifestations of hypoparathyroidism. Bone. 2019, 120:548-55. 10.1016\/j.bone.2018.11.012","journal-title":"Bone"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2019-00893","article-title":"Therapy of hypoparathyroidism with rhPTH(1-84): a prospective, 8-year investigation of efficacy and safety","volume":"104","author":"Tay YD","year":"2019","unstructured":"Tay YD, Tabacco G, Cusano NE, et al.. Therapy of hypoparathyroidism with rhPTH(1-84): a prospective, 8-year investigation of efficacy and safety. J Clin Endocrinol Metab. 2019, 104:5601-10. 10.1210\/jc.2019-00893","journal-title":"J Clin Endocrinol Metab"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-3910","article-title":"Management of hypoparathyroidism: present and future","volume":"101","author":"Bilezikian JP","year":"2016","unstructured":"Bilezikian JP, Brandi ML, Cusano NE, et al.. Management of hypoparathyroidism: present and future. J Clin Endocrinol Metab. 2016, 101:2313-24. 10.1210\/jc.2015-3910","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/415008-idiopathic-hypoparathyroidism-in-an-osteoporosis-patient-receiving-denosumab-therapy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T17:48:02Z","timestamp":1769708882000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/415008-idiopathic-hypoparathyroidism-in-an-osteoporosis-patient-receiving-denosumab-therapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,29]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.102570","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,29]]}}}